Short Communication - (2025) Volume 11, Issue 5
Received: 01-Oct-2025, Manuscript No. antimicro-26-183054;
Editor assigned: 03-Oct-2025, Pre QC No. P-183054;
Reviewed: 17-Oct-2025, QC No. Q-183054;
Revised: 22-Oct-2025, Manuscript No. R-183054;
Published:
29-Oct-2025
, DOI: 10.37421/2472-1212.2025.11.429
Citation: Dubois, Elise. ”Sustained Antimicrobial Delivery: Enhancing Treatment And Adherence.” J Antimicrob Agents 11 (2025):429.
Copyright: © 2025 Dubois E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The field of antimicrobial therapy is undergoing a significant evolution, driven by the urgent need to combat infectious diseases and the growing threat of antimicrobial resistance. A key area of innovation lies in the development of long-acting formulations that can provide sustained therapeutic levels of antimicrobial agents, thereby enhancing efficacy and improving patient adherence. This approach seeks to overcome the limitations of conventional dosing regimens, which often require frequent administration and can lead to fluctuating drug concentrations. Recent advancements in material science, drug delivery technologies, and pharmaceutical engineering are paving the way for sophisticated long-acting antimicrobial solutions. One prominent strategy involves the design and evaluation of advanced formulations that enhance drug delivery and prolong therapeutic efficacy. This includes novel drug encapsulation techniques, such as nano- and microparticle systems, which are crucial for achieving sustained release kinetics. These systems, enabled by progress in polymer science and material engineering, allow for controlled and targeted drug release, significantly minimizing dosing frequency and improving patient compliance for various infectious diseases [1].
The development of injectable sustained-release formulations for antibiotics represents another critical avenue of research. These formulations aim to achieve and maintain therapeutic concentrations for extended periods by utilizing various excipients and delivery vehicles. Liposomes and polymeric nanoparticles, for instance, facilitate slow drug diffusion and degradation, influencing drug release properties and impacting the reduction of bacterial resistance. Preclinical and clinical considerations for these advanced systems are also being actively explored [2].
Biodegradable polymers have emerged as a promising material for creating long-acting intramuscular injections of antibiotics. The synthesis and characterization of various polymer matrices demonstrate their capability to encapsulate and release drugs over weeks or months. In vitro drug release profiles and in vivo efficacy studies in animal models have shown sustained therapeutic levels and reduced bacterial loads, offering a promising approach for managing chronic and difficult-to-treat infections [3].
Nanotechnology-based formulations are also being extensively investigated for their potential to improve the pharmacokinetic and pharmacodynamic properties of antimicrobial agents. Nanoparticles can enhance drug solubility, stability, and enable targeted delivery to infection sites, leading to prolonged drug exposure and improved efficacy. This research also explores the potential of nanotechnology to overcome resistance mechanisms through optimized drug delivery [4].
The creation of novel long-acting implantable drug delivery systems for antibiotics is another area of significant interest. These systems are designed to release antimicrobial agents over extended periods, thereby reducing the need for frequent administration and improving patient compliance, especially in chronic infection settings. The fabrication process, drug loading efficiency, and in vitro release kinetics are detailed in various studies, alongside preliminary efficacy data in relevant infection models [5].
Injectable antimicrobial formulations are being developed to combat drug resistance, with a focus on strategies that enable sustained drug release. Microparticles, nanoparticles, and in-situ forming gels are among the formulation types being explored. The authors emphasize the importance of tailoring release profiles to specific pathogens and infection types, alongside the necessity for robust preclinical and clinical validation to improve treatment outcomes and reduce resistance development [6].
Stimuli-responsive drug delivery systems represent a cutting-edge approach to sustained antimicrobial release. These advanced formulations are designed to respond to specific physiological triggers at the infection site, such as pH or enzymes, to release the drug in a controlled manner. This targeted approach aims to maximize drug concentration where needed while minimizing systemic exposure and potential toxicity, offering benefits for chronic and localized infections [7].
Three-dimensional (3D) printing technology is being utilized for fabricating custom long-acting antimicrobial implants. This advanced manufacturing technique allows for precise control over implant geometry and drug loading, enabling the creation of patient-specific devices with tailored drug release profiles. The feasibility of printing drug-loaded implants with sustained release characteristics for treating localized conditions is being demonstrated [8].
In-situ forming gels are also being developed as long-acting delivery systems for antimicrobial agents. These systems transition from a liquid state to a solid gel upon injection, forming a depot that releases the drug over an extended period. Various gelling mechanisms and polymer choices are discussed, along with in vitro and in vivo studies demonstrating sustained drug levels and efficacy, offering a minimally invasive option for long-term antimicrobial therapy [9].
The challenges and opportunities in developing long-acting formulations for tuberculosis (TB) treatment are also being addressed. Strategies to maintain therapeutic concentrations of anti-TB drugs for extended periods are crucial for reducing pill burden and improving adherence. The review explores promising technologies, including microparticle and nanoparticle-based systems, and novel injectable formulations, highlighting their potential impact on global TB control efforts [10].
Sophisticated design and evaluation of long-acting antimicrobial formulations are central to enhancing drug delivery and prolonging therapeutic efficacy. Strategies like novel drug encapsulation techniques, including nano- and microparticle systems, are key to achieving sustained release kinetics. Advancements in polymer science and material engineering enable controlled and targeted drug release, thereby minimizing dosing frequency and improving patient adherence for various infectious diseases. Challenges and future directions in developing these advanced formulations are also discussed [1].
The development of injectable sustained-release formulations for antibiotics is a significant focus, aiming to achieve therapeutic concentrations for extended periods. Different excipients and delivery vehicles, such as liposomes and polymeric nanoparticles, are explored for their ability to facilitate slow drug diffusion and degradation. The physicochemical properties influencing drug release and the biological impact on reducing bacterial resistance are examined, along with preclinical and clinical considerations for these advanced delivery systems [2].
Biodegradable polymers are being investigated for their utility in creating long-acting intramuscular injections of antibiotics. Research details the synthesis and characterization of various polymer matrices, demonstrating their capacity to encapsulate and release drugs over weeks or months. In vitro drug release profiles and in vivo efficacy studies in animal models show sustained therapeutic levels and reduced bacterial loads, presenting a promising avenue for managing chronic and difficult-to-treat infections [3].
Nano-formulations are designed to improve the pharmacokinetic and pharmacodynamic properties of antimicrobial agents. Nanoparticles can enhance drug solubility, stability, and targeted delivery to infection sites, leading to prolonged drug exposure and improved efficacy. Detailed characterization of nanoparticle properties and performance assessments are included, along with discussions on overcoming resistance mechanisms through nanotechnology [4].
A novel approach to developing long-acting implantable drug delivery systems for antibiotics has been presented. These systems are designed to release antimicrobial agents over an extended period, reducing the need for frequent administration and improving patient compliance, particularly in chronic infection settings. The fabrication process, drug loading efficiency, and in vitro release kinetics are detailed, alongside preliminary efficacy data in relevant infection models [5].
Long-acting injectable antimicrobial formulations are being developed to combat drug resistance. Various formulation strategies, including microparticles, nanoparticles, and in-situ forming gels, that enable sustained drug release are reviewed. The authors discuss tailoring release profiles to specific pathogens and infection types, as well as the need for robust preclinical and clinical validation to improve treatment outcomes and reduce resistance development [6].
Stimuli-responsive drug delivery systems for sustained antimicrobial release are being investigated. These advanced formulations respond to specific physiological triggers at the infection site to release the drug in a controlled manner. This targeted approach aims to maximize drug concentration where needed while minimizing systemic exposure and potential toxicity, with potential impact on treating chronic and localized infections [7].
Three-dimensional (3D) printing technology is being explored for fabricating custom long-acting antimicrobial implants. This technology allows for precise control over implant geometry and drug loading, enabling patient-specific devices with tailored drug release profiles. The feasibility of printing drug-loaded implants with sustained release characteristics for treating localized conditions is demonstrated [8].
In-situ forming gels are being developed as long-acting delivery systems for antimicrobial agents. These systems solidify upon injection, forming a depot that releases the drug over an extended period. Various gelling mechanisms and polymer choices are discussed, alongside in vitro and in vivo studies demonstrating sustained drug levels and efficacy, offering a minimally invasive option for long-term antimicrobial therapy [9].
Long-acting formulations for tuberculosis (TB) treatment are a critical focus. Strategies for creating drug delivery systems that maintain therapeutic concentrations of anti-TB drugs for extended periods are reviewed. The challenges of achieving sustained release of multiple drugs and promising technologies, including microparticle and nanoparticle-based systems, are explored, emphasizing their potential impact on global TB control efforts [10].
Research into long-acting antimicrobial formulations aims to improve treatment efficacy and patient adherence by providing sustained drug release. Innovations include nano- and microparticle systems, biodegradable polymers, and injectable formulations like liposomes and nanoparticles. These technologies facilitate controlled drug delivery, minimizing dosing frequency and enhancing therapeutic outcomes. Advanced approaches like stimuli-responsive systems and 3D-printed implants offer personalized and targeted treatment options for various infections, including tuberculosis. The development of these formulations is crucial for combating antimicrobial resistance and improving global health.
None
None
Journal of Antimicrobial Agents received 444 citations as per Google Scholar report
